Diabetes mellitus and diabetes-related complications are common in patients with myelodysplastic syndromes but Hemoglobin A1C is an inadequate marker | Synapse
February 2, 2026Haematologica0 citationsOpen Access
To evaluate the prevalence of diabetes and its complications in patients with myelodysplastic syndromes, focusing on the effectiveness of Hemoglobin A1C as a monitoring tool.
Clinical assessment of patients diagnosed with myelodysplastic syndromes
Comparison of diabetes prevalence with standard markers
Analysis of diabetes-related complications within the cohort
Diabetes mellitus and related complications are prevalent in myelodysplastic syndrome patients.
Hemoglobin A1C failed to accurately reflect glucose control in this population.
Alternative markers may be necessary for effective diabetes monitoring.